- Written by: web web
- Hits: 90
Chief Executive Officer
Matthias Alder serves as Chief Executive Officer and Director of Gain Therapeutics. He joined the Company in 2021 as Chief Operating Officer with more than 25 years of transactional, operational, and business development experience in the pharmaceutical and biotechnology industries. Previously, Mr. Alder was Chief Business Officer at Autolus Therapeutics, a biotechnology company focused on developing CAR T-cell therapies for hematological and solid tumors, where he led the corporate development, legal, IP and HR functions. Prior to joining Autolus, he served as EVP of Business Development & Licensing and General Counsel of Sucampo Pharmaceuticals. During his tenure there, Mr. Alder established a late-stage development pipeline in orphan and rare CNS and oncology indications through acquisitions and strategic alliances. He has also held executive management positions at Cytos Biotechnology AG as EVP Corporate Development and General Counsel, and Micromet, Inc. as SVP Administration and General Counsel. Earlier in his career, Matthias was a partner in the Life Sciences Transactions Practice at Cooley LLP and in-house counsel for Novartis’ pharmaceutical business. Matthias earned his LL.M. in Comparative Law from Miami University, his lic. Iur. from the University of Basel and is a member of the Virginia, California, New York and Zurich bar associations.
Manolo Bellotto, Ph.D.
Chief Strategy Officer and General Manager
Dr. Manolo Bellotto serves as Chief Strategy Officer and General Manager of Gain Therapeutics. He joined the Company in 2018 with more than 20 years of experience in international pharmaceutical product, medical and advocacy development, commercialization, and international research collaborations in major and rare/orphan disease indications across various continents. Previously, Dr. Bellotto served as director of strategic projects at Mederis, a service provider for pharmaceutical, medical device and medical food companies providing assessment, prioritization, planning and management of product development, medical and market-shaping activities. He developed his career as the director of business development at Aptitude Health, a global healthcare company focusing on oncology insights for the life sciences industry. Dr. Bellotto has also previously served as global product leader at Vifor Pharma, a global specialty pharmaceutical company. Dr. Bellotto has held various positions, such as head of international product management and head of marketing, at Helsinn Healthcare, DKSH Healthcare, European Society for Medical Oncology (ESMO), and Chemo SA. Dr. Bellotto received a Ph.D. in Molecular Developmental Genetics from the University of Zurich after having studied molecular biology at the Biocentre of the University of Basel and at the Fredrich Miescher Institute for Biomedical Research in Basel.
C. Evan Ballantyne
Chief Financial Officer
C. Evan Ballantyne serves as Chief Financial Officer of Gain Therapeutics. He joined the Company in 2023 with more than 20 years of experience managing the financing and corporate strategy of publicly traded and private companies in the healthcare industry. Prior to joining Gain, he was Chief Financial Officer of OncXerna Therapeutics, Inc., where he helped raise $30 million in an equity financing round. Prior to OncXerna, Mr. Ballantyne served as Chief Financial Officer of Orchestra Biomed, Inc., where he facilitated the closing of equity financing rounds with gross proceeds of $57 million and assisted in the development of a global partnership valued at more than $200 million. Prior to his time at Orchestra Biomed, Mr. Ballantyne served as Chief Financial Officer of Cerecin, Inc., a biotechnology company backed by Nestlé Health Science. Mr. Ballantyne previously served as Executive Vice President and Chief Financial Officer of Clinical Data, Inc., a public biotechnology company that was acquired by Forest Laboratories (now AbbVie) for $1.2 billion, and as Chief Financial Officer of Agenus, Inc. (NASDAQ: AGEN) and Synthetic Biologics, Inc. (NYSE: SYN). Mr. Ballantyne holds a B.A. in history and political science from the University of Western Ontario and a post-graduate degree in business administration from the University of Windsor.
Terenzio Ignoni, Pharm.D.
SVP Technical Operations
Terenzio Ignoni, Pharm.D.
SVP Technical Operations
Dr. Terenzio Ignoni, joined Gain Therapeutic in June 2021 as SVP Quality and CMC bringing with him more than 22 years of hands-on experience in pharmaceutical technical operations, quality and regulatory CMC with a successful track record of drug approvals in multiple jurisdictions, notably: Europe, USA, Canada, Japan, Australia and Latin America. Before joining Gain, Terenzio was VP Quality and QP at Jazz Pharmaceuticals (JAZZ NASDAQ), a global biopharmaceutical company focused on neuroscience and oncology rare diseases. During his tenure at Jazz, Terenzio lead product submissions, technical due diligences and site pre-approval inspections from US-FDA, PMDA, ANVISA, EMA. Prior to Jazz Pharmaceutical, Terenzio held the position of VP Quality at Gentium a biopharmaceutical company specialized in the development and manufacturing of biopharmaceutical products. During his time at Gentium, he was in charge of the development and deployment of the quality system, technical operations (manufacturing and control) and CMC regulatory strategy leading to the EMA approval of the drug lead candidate in 2013 and of the merge of the company with Jazz Pharmaceuticals in 2014. Terenzio started his career as Quality Control supervisor at Biosearch manufacturing (merged into Vicuron/Pfizer), a company specialized in the development and manufacturing of antibiotics agents and as Analytical Development & Quality Control Manager of Zambon Group (Lonigo manufacturing site). Terenzio received a Pharm.D. from the University of Turin, Italy.
Dr. Joanne Taylor
Dr. Joanne Taylor, Ph.D. has served as a scientific advisor to Gain since September 2020. Dr. Taylor has over 25 years’ experience in the pharmaceutical industry and has consulted for various pharma and biotech clients since 2018. She also developed her career as vice president, head of neuroscience for Prescient Healthcare Group where she headed up their neuroscience business (comprising neurology, psychiatry, ophthalmology, rare diseases and pain), supporting the portfolio, clinical and regulatory strategies of a wide array of global top 25 pharmaceutical company clients. She also served as director of external research, neuroscience and previously as a senior group leader and scientist at Eisai’s London Research Laboratories and European Headquarters where she directed global teams in the discovery of novel therapeutic strategies for neurological conditions, in particular Alzheimer’s, multiple sclerosis and Parkinson’s disease. There she later led neuroscience portfolio reviews to identify areas of major focus and investment, as well as partnering activities with academia and biotech. Dr. Taylor received a Ph.D. in in Developmental Neuroscience from King’s College and completed a postdoctoral fellowship and senior research post at the ETH in Zurich.